Novo Nordisk reported that oral Wegovy showed "significantly greater mean weight loss" than Lilly's rival oral GLP-1, Foundayo, which was approved this week. The comparison was based on evaluations of previously published studies and did not include any new patient-level data or fresh trial results. The claim reinforces Novo's competitive positioning in the oral obesity/GLP-1 market, but without new data is unlikely to change regulatory status or materially move markets.
Novo Nordisk reported that oral Wegovy showed "significantly greater mean weight loss" than Lilly's rival oral GLP-1, Foundayo, which was approved this week. The comparison was based on evaluations of previously published studies and did not include any new patient-level data or fresh trial results. The claim reinforces Novo's competitive positioning in the oral obesity/GLP-1 market, but without new data is unlikely to change regulatory status or materially move markets.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
